Marvell put a $1,132 price on each Lumentum share Monday. That number was out of date before the market opened.

The deal pays in Marvell stock, and the price was measured on Oct. 28. Marvell has lost about a third since then. On announcement day both stocks fell more than 13%. Lumentum fell 17% on a morning it also beat forecasts and raised its outlook.

A morning rally faded as chip stocks fell again. In afternoon trading the Dow was up about 0.6%, while the S&P 500 slipped about 0.3% and the Nasdaq about 0.7%.

3 MOVERS IN 3 MINUTES

1. Oil fell 8%. The Fed bet didn't budge.

U.S. crude fell nearly 8% to about $96 a barrel as reports of U.S.-Iran diplomacy spread. Rate bets didn't follow.Kalshi's December hike contract traded at 73 cents in early afternoon, up from 71 cents overnight. A strong factory report helps explain it. The ISM manufacturing index rose to 55.5, and its production gauge hit its highest level since November 2021, even as prices paid cooled. One reading is that traders now see the hiking case as bigger than energy.

2. Oracle set a $20 billion limit. Five days later it used all of it.

On Oct. 28, Oracle (ORCL) promised to cap new capital raises through fiscal 2030 at $10 billion of stock and $10 billion of debt. On Monday it filed to sell both halves, and the shares fell about 9%, erasing the promise-day rally. Hours later, the Fed's loan officer survey showed banks tightening standards on every loan type to nonbank lenders, including private equity funds. The survey doesn't mention AI. But borrowers who turn to private credit will find its lenders facing tighter bank terms.

3. Strategy spent more buying back its preferred than buying bitcoin.

Strategy (MSTR) bought 811 bitcoin last week for $65.5 million. It spent $208.2 million, about three times as much, buying back its STRC preferred stock. With bitcoin near $76,800, its 849,327 coins are worth less than 2% more than it paid. The filing doesn't say why. Either way, cash that once went almost entirely to bitcoin is now being split.

3 SIGNALS FOR TOMORROW

1. Apple and Palantir report tonight. Apple (AAPL) reports after the close, with analysts expecting about $1.99 a share. On Friday we asked whether it would echo Intel's warning on memory costs. What it could change: a memory complaint from Apple turns a PC problem into a device problem. Palantir (PLTR) also reports tonight.

2. The midterms. Polls close Tuesday.Kalshi priced Democratic Senate control at 73 cents early Monday, but a race that comes down to Alaska could take weeks to count. What it could change: control of Congress shapes spending and Treasury supply, and Treasury sets its borrowing plans Wednesday morning. A slow count leaves that question open longer.

3. AMD reports Tuesday. AMD (AMD) is expected to earn $1.95 a share on about $13.1 billion of revenue. It fell about 11% Friday and about 7% more Monday before saying a word. What it could change: AMD sells PC, data-center and AI chips, so its outlook is the first clean test of whether Intel's memory warning spreads past PCs.

Now, back to Marvell.

PREMIER FEATURE

7 Stocks That Could Become the Market’s Next Giants

Apple, Google, Tesla…

Sure, they’re household names now, but these companies and the other members of the original Magnificent 7 didn’t start out obvious.

They earned their place over time.

Our analysts believe the next generation of market leaders is forming now…

And we’ve identified the 7 companies that fit the “Magnificent” pattern.

You can see the full list for free today

Don’t wait until everyone’s talking about them.

Get Your Free Report Today.

The Sip

Marvell is buying Lumentum with a currency that keeps falling

Marvell (MRVL) agreed to buy Lumentum (LITE) for 4.5 Marvell shares per Lumentum share. The companies put the implied enterprise value at $115 billion, or about $1,132 a share, a 23.9% premium. Both numbers use Oct. 28 closing prices, the last day before deal talk began.

That date matters more than the premium.

The price was set in a different market

When talks leaked that evening, the first verdict was that the buyer pays. Marvell has fallen about a third since that close. Near $170 on Monday afternoon, 4.5 Marvell shares were worth about $763. That is roughly 16% less than Lumentum fetched on Oct. 28, before anyone had heard of a deal.

At today's prices the premium is a discount. And because the ratio is fixed, every dollar Marvell loses passes straight through to Lumentum holders.

A beat that couldn't lift the stock

Lumentum also reported early on Monday. Revenue reached $1.26 billion, and it guided next quarter to $1.575 billion to $1.625 billion, above the roughly $1.48 billion analysts expected, according to Investing.com. The stock still fell about 17%. Its value now rides on someone else's share price.

In afternoon trading, Lumentum sat about 11% below the value of its 4.5 Marvell shares. That gap is the market's price for time and risk. The companies don't expect to close until the first half of 2028, and the deadline can stretch to August 2028 if regulators need longer.

Marvell's holders pay twice

They give up about a third of the combined company. They must also vote to approve the new shares and a charter change that authorizes more stock.

The contract shows how much Marvell wants this done. It owes Lumentum $5.8 billion if the deal ends in certain circumstances, and $3.2 billion in certain regulatory cases. Lumentum's fee is $2.9 billion.

The strategic case is real. Marvell's signal-processing chips and Lumentum's lasers would sit under one roof. The companies promise more than $1 billion of yearly cost savings and say the deal adds to Marvell's adjusted earnings in its first year after closing.

The cost of paying in stock

Marvell's shares had nearly tripled this year before the talks leaked, which made paying in stock look painless. A fixed ratio ties the seller to the buyer's chart, and that chart now moves with a chip sector still digesting Intel's warning.

What settles it

The merger filing will name the regulators and set the votes. A narrowing gap means growing faith in the deal. A widening one means doubt about the timeline or Marvell's stock.

PARTNER SPOTLIGHT

You’re Being LIED To About The Iran War

Forget EVERYTHING you’ve heard about the Iran war.

Especially the reasons why we’re bombing the country.

Because THIS is the real reason. →

The Market Sips Takeaway

An all-stock deal is only as good as the buyer's stock.

  • What would confirm the deal is priced as safe: the gap between Lumentum and 4.5 Marvell shares narrows once the merger filing lands.
  • What would break it: the gap widens, the filing shows a long regulatory list, or Marvell holders balk at the vote.
  • Where it shows up next: optical suppliers such as Coherent and Ciena, and any AI hardware buyer planning to pay in stock.

Lumentum holders didn't sell for $1,132. They sold for 4.5 Marvell shares, whatever those turn out to be worth.

UNTIL THEN, SIP SLOWLY!

The Market Sips Desk

If you were selling your company, would you take a smaller premium in cash or a bigger one in stock? Hit reply and tell us.

Big Pharma Stopped Watching AI Drug Discovery. It Started Paying.

Sanofi has paid one AI biotech $144 million in upfront and milestone payments. Eli Lilly invested $40 million in another. Bristol Myers Squibb is putting a third company's AI co-scientist to work inside its own research organization.
The industry's biggest drugmakers used to watch this technology from the sidelines. Now they're customers.
We profiled the 5 companies leading AI drug development in a new FREE Special Report: AI Moves Into the Biotech Lab.
We'll text it straight to your phone.

Get the Free Report by Text →